1530 On Other Exchanges
1530 is not on other exchanges.

3sbio inc (1530) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 3SBIO INC (1530)

3sbio inc (1530) Related Bloomberg News

View More Bloomberg News

3sbio inc (1530) Related Businessweek News

No Related Businessweek News Found

3sbio inc (1530) Details

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. Its products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; and EPIAO, an injectable recombinant human erythropoietin for anemia associated with chronic kidney disease (CKD) and chemotherapy, as well as to reduce allogeneic blood transfusion in surgery patients. The company also offers IV Iron Sucrose, an iron sucrose injection product for iron deficiency anemia; SEPO, an injectable product for anemia associated with CKD, as well as CIA; and Sparin, an injectable low-molecular-weight heparin calcium product for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. In addition, it provides Intefen, a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; Inleusin, a recombinant human interleukin 2 product for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; and Gan Xin, a metadoxine drug for alcoholic liver disease. Further, the company offers Qiming Keli for Type 2 diabetic retinopathy; Yi Li Xi, a TZDS antidiabetic drug; Man di, an OTC drug for baldness; Lai Zi, a tacrolimus ointment for atopic dermatitis; Di Su, a BCG-PSN injection for chronic bronchitis, cold, and asthma; Lai Duo Fei for allergic rhinitis and antihistamines; Liranaftate, a glucosinolates carbamate antifungal drug for the treatment of tinea pedis, tinea corporis, and tinea cruris; and Amikacin to treat trauma infection caused by bacteria, as well as distributes anti-cancer drugs, such as Docetaxel, Anastrozole, and Azasetron. 3SBio Inc. sells its products to hospitals and medical institutions through in-house sales and marketing team, distributors, and third-party promoters. The company was incorporated in 2006 and is headquartered in Shenyang, the People’s Republic of China. 3SBio Inc. is a subsidiary of Decade Sunshine Limited.

3,690 Employees
Last Reported Date: 09/28/17
Founded in 2006

3sbio inc (1530) Top Compensated Officers

Co-Founder, Chairman, CEO & President
Total Annual Compensation: CNY432.0K
CFO, Executive VP & Executive Director
Total Annual Compensation: CNY518.0K
Senior VP & Executive Director
Total Annual Compensation: CNY668.0K
VP & Executive Director
Total Annual Compensation: CNY480.0K
Compensation as of Fiscal Year 2016.
3sbio inc
3SBio Inc Announces 601A Approval for Investigational New Drug Application from CFDA for Clinical Trials

The board of directors of 3SBio Inc. announced that a Recombinant Humanized Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for Injection has been granted an approval by the China Food and Drug Administration in respect of the Investigational New Drug application for clinical trials. The Recombinant Humanized Anti-VEGF Monoclonal Antibody for Injection was developed by one of the subsidiaries of the company, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. The Group is currently actively preparing for clinical trials of the Product. The group intends to develop the Product for the treatment of neovascular age-related macular degeneration. AMD has become one of the main causes of irreversible blindness of elder people. As shown in an epidemiologic study in the United States, the prevalence rate of AMD was approximately 2% for people aged from 52 to 64, and increased to approximately 28% for people aged 75 or above. The prevalence rate of AMD in China has been increasing significantly in recent years as the aging population has increased in China.

3SBio Inc. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017

3SBio Inc. reported unaudited consolidated earnings results for the six months ended June 30, 2017. For the period, revenue was RMB 1,706,735,000 against RMB 1,304,866,000 a year ago. Profit before tax was RMB 483,280,000 against RMB 352,595,000 a year ago. Profit for the period attributable to owners of the parent was RMB 392,764,000 against RMB 286,852,000 a year ago. Diluted earnings per share were RMB 0.15 against RMB 0.11 a year ago. Net cash flows from operating activities were RMB 350,362,000 against RMB 394,837,000 a year ago. Purchase of items of property, plant and equipment was RMB 73,283,000 against RMB 38,559,000 a year ago.

3SBio Inc. Presents at 2017 Silicon Valley Bank Healthcare Capital and Connections Summit, Sep-13-2017 11:15 AM

3SBio Inc. Presents at 2017 Silicon Valley Bank Healthcare Capital and Connections Summit, Sep-13-2017 11:15 AM. Venue: Intercontinental Shanghai Rujin, Shanghai, China. Speakers: James Zhang, Vice President.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1530.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1530 Industry Range
Price/Earnings 100.0x
Price/Sales 89.0x
Price/Book 41.4x
Price/Cash Flow 3.2x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3SBIO INC, please visit www.3sbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.